The National Institutes of Health Publication 02-5053, Cancer Clinical Trials: A Resource Guide for Outreach, Education, and Advocacy, helps individuals and organizations find ways to participate and engage their community in clinical trials outreach and education activities. This publication includes worksheets and a Plan for Action to plan outreach efforts. Whether you are a health care professional who wants to find ways to reach your community, a member of a patient group who wants to educate its members, or someone who want to engage your group or organization to initiate clinical trial outreach activities. This guide is not designed to be a comprehensive overview; rather, it gives some examples of activities others have engaged in, and provides tools and suggestions for implantation in your community. By informing your community about clinical trials, you can help people make informed decisions about their cancer treatment or prevention options, including the option of participation in a clinical trial. The more people that participate in clinical trials, the faster we can answer the critical research questions that will lead us to better treatment and prevention options for all cancers. This workbook is designed to complement the other materials in the National Cancer Institute Clinical Trials Education Series, described at the beginning of this book.~
The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research.
Ultimately, the cancer patients will be benefited. "Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations.
The book discusses clinical trials from start to finish focusing on real-life examples in the development, design and analysis of clinical trials.
Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop.
Suitable for cancer clinicians and biostatisticians, this book shows how randomized phase II trials with a prospective control resolve the shortcomings of traditional single-arm phase II trials.
The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies.
To explore innovative paradigms for cancer clinical trials and other ways to improve their quality, the National Cancer Policy Forum held a workshop, Improving the Quality of Cancer Clinical Trials, in Washington, DC. The main goals of the ...
Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto I., and Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient.
Breakthrough therapy designation was enacted on July 9, 2012, with the ratification of the Food and Drug Administration Safety and Innovation Act (FDASIA). Section 902 of FDASIA provides the two general criteria for a drug to receive ...
New to this edition are chapters on Phase 0 Trials and Immunotherapeutics, and updated information on the process, pitfalls, and logistics of Phase I Trials